Clinical Trial Detail

NCT ID NCT02005471
Title A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

chronic lymphocytic leukemia

Therapies

Venetoclax

Bendamustine

Rituximab

Age Groups: adult

No variant requirements are available.